ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC
Clinical Lung Cancer · 2026-06 · 27 (5) · 65-76.e2
DOI: 10.1016/j.cllc.2026.04.003 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Lung Cancer, 2026-06. Verfasst von Marina Chiara Garassino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology Oncology, The University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Docetaxel, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 39 Literaturangaben. Gefördert von: GlaxoSmithKline.
Abstract (Originalsprache)
BACKGROUND Combining treatments with different mechanisms may improve immunosurveillance and outcomes in advanced/recurrent non-small cell lung cancer (NSCLC) after immunotherapy. ENTRÉE Lung (NCT03739710) is a phase 2, open-label platform trial utilizing a master protocol to investigate novel regimens versus standard of care (SoC) in separate sub-studies. Sub-study 1 investigated the immunoglobulin G4 inducible T-cell costimulator agonist antibody, feladilimab, plus docetaxel versus SoC, docetaxel monotherapy. PATIENTS AND METHODS Patients with advanced/recurrent NSCLC who progressed on prior anti-programmed cell death (ligand)-1 and platinum-based combination chemotherapies were randomized to feladilimab (80 mg) plus docetaxel 75 mg/m2 (both intravenous) or docetaxel 75 mg/m2 every 3 weeks until progressive disease/unacceptable toxicity. The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS), tumor response (including overall response rate [ORR]), and safety. Exploratory endpoints included biomarkers. RESULTS A total of 105 patients were randomized to feladilimab plus docetaxel (n = 70) or docetaxel (n = 35). Median OS was 7.8 months with feladilimab plus docetaxel versus 8.2 months with docetaxel; hazard ratio (HR) 1.5 (95% confidence interval [CI], 0.92, 2.44). Median PFS for feladilimab plus docetaxel versus docetaxel was 3.4 months versus 3.3 months, and ORR was 19% versus 11%; HR 0.84 (95% CI, 0.54, 1.32). Most frequently reported treatment-related adverse events included anemia (34% vs. 24%), nausea (34% vs. 15%), alopecia (27% vs. 21%), and asthenia (27% vs. 18%). CONCLUSION Feladilimab plus docetaxel has an acceptable safety profile in the second-line treatment of advanced/recurrent NSCLC. No survival outcomes or tumor response advantages were observed with the addition of feladilimab to docetaxel in this setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology Oncology, The University of Chicago, Chicago, IL.
- Early Phase Trials and Thoracic Unit, Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
- Department of Cancer Medicine, Gustave Roussy, Villejuif, Paris-Sud University, Orsay, France.
- Department for Adrian Sacher, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
- Department of Oncology, I.P. Pavlov St.-Petersburg State Medical University, St. Petersburg, Russia.
- Centrul de Oncologie Sf. Nectarie, Oncologie Medicala, Craiova, Romania; Cancer Institute I Chiricuta, Cluj, Romania.
Förderung
- GlaxoSmithKline
Zitieren
APA
Garassino, M. C., Cousin, S., Besse, B., Sacher, A., Orlov, S., Schenker, M., Felip, E., Gladkov, O., Messina, C. H., Majumdar, A., Wu, Z. J., Karpinich, N. O., Hirschfeld, S., Ballas, M., & Reck, M. (2026). ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC. Clinical Lung Cancer, 27(5), 65-76.e2. https://doi.org/10.1016/j.cllc.2026.04.003
Vancouver
Garassino MC, Cousin S, Besse B, Sacher A, Orlov S, Schenker M, et al. ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC. Clinical Lung Cancer. 2026;27(5):65-76.e2. doi:10.1016/j.cllc.2026.04.003
BibTeX
@article{Garassino2026,
author = {Garassino, Marina Chiara and Cousin, Sophie and Besse, Benjamin and Sacher, Adrian and Orlov, Sergey and Schenker, Michael and Felip, Enriqueta and Gladkov, Oleg and Messina, Cristina H and Majumdar, Antara and Wu, Zhenhua Jeremy and Karpinich, Natalie O and Hirschfeld, Steven and Ballas, Marc and Reck, Martin},
title = {ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC},
journal = {Clinical Lung Cancer},
year = {2026},
volume = {27},
number = {5},
pages = {65--76.e2},
doi = {10.1016/j.cllc.2026.04.003}
}
EUVIMED